Business Context and Reporting Period
This Form 8-K, dated May 30, 2023, is filed by Angion Biomedica Corp. (ANGN) regarding a proposed merger with Elicio Therapeutics, Inc. The filing serves as an update to the Agreement and Plan of Merger entered into on January 17, 2023. The transaction has not yet been consummated.
Key Financial Metrics
The filing does not provide specific revenue, profit, cash flow, margin, debt, or liquidity figures for either company. The primary financial disclosure is the final Exchange Ratio for the merger.
- Final Exchange Ratio: 0.0181
- Assumption: This ratio assumes a 10-for-1 reverse stock split of Angion common stock.
Material Changes
The material change disclosed is the confirmation of the final Exchange Ratio for the merger transaction previously announced in January 2023. No other operational or financial changes are detailed in this specific report.
Guidance, Outlook, and Risks
Management notes that the Exchange Ratio is a forward-looking statement subject to risks and uncertainties. Key risks and contingencies include:
- Completion of the Merger, which requires stockholder approval and satisfaction of closing conditions.
- Angion's ability to remain listed on the Nasdaq Global Market.
- Events or circumstances that could lead to the termination of the Merger Agreement.
Investors are urged to review the proxy statement/prospectus/information statement filed on April 28, 2023, for a comprehensive discussion of risk factors.
Important Facts for Investors to Verify
- Confirm the final Exchange Ratio of 0.0181 and the impact of the 10-for-1 reverse stock split on share ownership.
- Verify the status of stockholder approval and other closing conditions required to consummate the merger.
- Review the full proxy statement/prospectus/information statement (File No. 333-269741) for detailed risk factors and transaction terms.
- Note that this filing is informational and does not constitute an offer to sell or a solicitation of a vote.